Hikal’s active pharmaceutical ingredient (API) and Intermediates manufacturing facility located at Jigani, Bengaluru was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements. At the end of the successful inspection, the company has been informed by the Investigator that ‘zero’ 483 observations were issued. This was a routine inspection by the USFDA.
Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries. It collaborates with innovator companies and offer solutions in Contract Research, Custom Synthesis and Custom Manufacturing.
